Evidence map›Paper›PMID 34697505›Full record

ArticleJournal of molecular structure2022

Design and synthesis of heterocyclic azole based bioactive compounds: Molecular structures, quantum simulation, and mechanistic studies through docking as multi-target inhibitors of SARS-CoV-2 and cytotoxicity.

Jebiti Haribabu, Vasavi Garisetti, Rahime Eshaghi Malekshah, Swaminathan Srividya, Dasararaju Gayathri, Nattamai Bhuvanesh, Ramalinga Viswanathan Mangalaraja, Cesar Echeverria, Ramasamy Karvembu

Abstract read
In one paragraph

Article in Journal of molecular structure, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jebiti HaribabuDepartment of Chemistry, National Institute of Technology, Tiruchirappalli 620015, India.
Vasavi GarisettiCentre of Advanced Study in Crystallography and Biophysics, University of Madras, Guindy Campus, Chennai 600025, India.
Rahime Eshaghi MalekshahMedical Biomaterial Research Centre (MBRC), Tehran University of Medical Sciences, Tehran, Iran.
Swaminathan SrividyaDepartment of Chemistry, National Institute of Technology, Tiruchirappalli 620015, India.
Dasararaju GayathriCentre of Advanced Study in Crystallography and Biophysics, University of Madras, Guindy Campus, Chennai 600025, India.
Nattamai BhuvaneshDepartment of Chemistry, Texas A & M University, College Station, TX 77842, USA.
Ramalinga Viswanathan MangalarajaAdvanced Ceramics and Nanotechnology Laboratory, Department of Materials Engineering, Faculty of Engineering, University of Concepcion, Concepcion, Chile.
Cesar EcheverriaFacultad de Medicina, Universidad de Atacama, Los Carreras 1579, 1532502 Copiapo, Chile.
Ramasamy KarvembuDepartment of Chemistry, National Institute of Technology, Tiruchirappalli 620015, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Two heterocyclic azole compounds, 3-(2,3-dihydrobenzo[d]thiazol-2-yl)-4H-chromen-4-one (

Indexed as

CytotoxicityHeterocyclic azolesMolecular dockingMulti-target inhibitorsQuantum simulationSARS-CoV-2

Identifiers

PMID34697505
PMCPMC8528790

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.